

# Asthma and COPD Drug Market 2026

<https://marketpublishers.com/r/A21F193A2BFAEN.html>

Date: November 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: A21F193A2BFAEN

## Abstracts

The Asthma and COPD Drug Market was valued at in and is anticipated to reach by , at a CAGR of 0.039 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Asthma and COPD Drug Market.

This report delivers a comprehensive overview of the Asthma and COPD Drug Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Asthma and COPD Drug Market. The Asthma and COPD Drug Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Asthma and COPD Drug Market Scope:

By Diseases

Asthma

COPD

By Spectrum

Combination Drugs

Inhaled Corticosteroids (ICS)

Short-Acting Beta Agonists (SABA)

Long-Acting Beta Agonists (LABA)

Leukotriene Antagonists (LTA)

Anticholinergics

Others

By Distribution Channel

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Key Players

AstraZeneca PLC

Boehringer Ingelheim GmbH

GlaxoSmithKline PLC

Novartis AG

Hoffmann-La Roche Ltd

Pfizer Inc.

Grifols SA

Merck & Co. Inc.

Sanofi SA

Sumitomo Dainippon Pharma Co. Ltd

## Major Highlights

This report delivers a comprehensive overview of the Asthma and COPD Drug Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Asthma and COPD Drug Market. The Asthma and COPD Drug Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

### Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. MARKET DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Market Snippet By Diseases
- 3.2. Market snippet By Diseases
- 3.3. Market Snippet By Distribution Channel
- 3.4. Market Snippet by Region

### **4. MARKET DYNAMICS**

- 4.1. Market Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Technological advancements in novel drugs
    - 4.1.1.2. Stringent Government Regulations for the Product Approval ?
  - 4.1.2. Restraints:
    - 4.1.2.1. The growing prevalence of asthma and COPD Drug resistance
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Regulatory Analysis

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of Covid-19 on the Market
  - 6.1.1. Before COVID-19 Market Scenario
  - 6.1.2. Present COVID-19 Market Scenario
  - 6.1.3. After COVID-19 or Future Scenario

- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturer's Strategic Initiatives
- 6.6. Conclusion

## **7. BY DISEASES**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases Segment
  - 7.1.2. Market Attractiveness Index, By Diseases Segment
- 7.2. Asthma\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3. COPD

## **8. BY SPECTRUM**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Spectrum
  - 8.1.2. Market Attractiveness Index, By Spectrum
- 8.2. Combination Drugs\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3. Inhaled Corticosteroids (ICS)
- 8.4. Short-Acting Beta Agonists (SABA)
- 8.5. Long-Acting Beta Agonists (LABA)
- 8.6. Leukotriene Antagonists (LTA)
- 8.7. Anticholinergics
- 8.8. Others

## **9. BY DISTRIBUTION CHANNEL**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
- 9.2. Hospital Pharmacy\*

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

9.3. Online Pharmacy

9.4. Retail Pharmacy

9.5. Others

## **10. BY REGION**

10.1. Introduction

10.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. The U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. U.K.

10.3.6.3. France

10.3.6.4. Italy

10.3.6.5. Spain

10.3.6.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
  - 10.5.1. Introduction
  - 10.5.2. Key Region-Specific Dynamics
  - 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases
  - 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Spectrum
  - 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    - 10.5.6.1. China
    - 10.5.6.2. India
    - 10.5.6.3. Japan
    - 10.5.6.4. Australia
    - 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
  - 10.6.1. Introduction
  - 10.6.2. Key Region-Specific Dynamics
  - 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases
  - 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  - 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

## **11. COMPETITIVE LANDSCAPE**

- 11.1. Key Developments and Strategies
- 11.2. Company Share Analysis
- 11.3. Product Benchmarking

## **12. COMPANY PROFILES**

- 12.1. AstraZeneca PLC\*
  - 12.1.1. Company Overview
  - 12.1.2. Product Portfolio and Description
  - 12.1.3. Key Highlights
  - 12.1.4. Financial Overview

- 12.2. Boehringer Ingelheim GmbH
- 12.3. GlaxoSmithKline PLC
- 12.4. Novartis AG
- 12.5. Hoffmann-La Roche Ltd
- 12.6. Pfizer Inc.
- 12.7. Grifols SA
- 12.8. Merck & Co. Inc.
- 12.9. Sanofi SA
- 12.10. Sumitomo Dainippon Pharma Co. Ltd (\*LIST NOT EXHAUSTIVE)

### **13. DATAM INTELLIGENCE**

- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us

## I would like to order

Product name: Asthma and COPD Drug Market 2026

Product link: <https://marketpublishers.com/r/A21F193A2BFAEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A21F193A2BFAEN.html>